NEW DRUG AGAINST OBESITY

Description

Obesity is considered the pandemic of the 21st century by the World Health Organization. In 2022, 16% of adults worldwide were obese.
It is characterized by a high BMI (>30) and is one of the main risk factors for other diseases such as diabetes, cancer and cardiovascular and musculoskeletal diseases.
However, the availability of treatments and their effectiveness is limited, with the most widespread therapy currently being a reduction in caloric intake and increased exercise.
The present invention relates to a new treatment against obesity based on the use of a microRNA and a drug targeting system for adipose tissue.

Advantages

A nanosystem consisting of a gold nanoparticle + surfactants + miRNA acts as a drug against obesity and a nanosystem targeting system that allows its specific capture by adipose tissue (AT) in localized areas.
The miRNA acts on white TA (energy storage) transforming it into beige TA (with thermogenic activity) while activating thermogenesis in both beige TA and brown TA (thermogenic activity).

Uses and Applications

The nanosystem and the targeting system have been validated in an animal model of obesity, obtaining, among others, evidence of:
- Decreased weight gain in animals fed a high-fat diet
- Overexpression of miRNA in the tissue.
- Overexpression of the thermogenesis pathway

Keywords

Sectors

Areas

Applicants

UNIVERSIDAD DE MÁLAGA, SERVICIO ANDALUZ DE SALUD (SAS), UNIVERSIDAD DE SEVILLA. VICERRECTORADO DE INVESTIGACIÓN, CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, M.P.

Inventors

RAJAA EL BEKAY RIZKY, SAID LHAMYANI , ADRIANA MARIEL GENTILE , MARÍA MENGUAL MESA, ADNAN BOUAOUDA ARAFA, ROSA MARÍA GIRÁLDEZ PÉREZ, ELIA MARÍA GRUESO MOLINA

Filing Date

19/01/2024 

Protection Level: Worldwide (PCT countries)

Processing Status: Wordwide (PCT countries) protection application